The therapeutic potential of p53 reactivation by nutlin-3a in ALK anaplastic large cell lymphoma with wild-type or mutated p53. (Q39801328)

14 September 2017

title

The therapeutic potential of p53 reactivation by nutlin-3a in ALK anaplastic large cell lymphoma with wild-type or mutated p53. (English)

1 reference

14 September 2017

E Drakos

1

1 reference

14 September 2017

V Atsaves

2

1 reference

14 September 2017

E Schlette

3

1 reference

14 September 2017

J Li

4

1 reference

14 September 2017

I Papanastasi

5

1 reference

14 September 2017

G Z Rassidakis

6

1 reference

14 September 2017

L J Medeiros

7

1 reference

14 September 2017

publication date

10 September 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

23

1 reference

14 September 2017

issue

12

1 reference

14 September 2017

page(s)

2290-2299

1 reference

The anaplastic lymphoma kinase in the pathogenesis of cancer

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Restoration of p53 function leads to tumour regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Modeling the therapeutic efficacy of p53 restoration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Caspase-3 activation in systemic anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Intrinsic apoptotic pathway in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

PUMA couples the nuclear and cytoplasmic proapoptotic function of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Transcription, apoptosis and p53: catch-22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

inferred from DOI database lookup

7 January 2021

based on heuristic

BCL‐2 family proteins in peripheral T‐cell lymphomas: correlation with tumour apoptosis and proliferation

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

inferred from DOI database lookup

7 January 2021

based on heuristic

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

1 reference

https://api.crossref.org/works/10.1038/LEU.2009.180

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2009.180

1 reference

14 September 2017

1 reference